TUDCA (tauroursodeoxycholic acid) for liver and bile flow: what trials show

TUDCA is the taurine-conjugated form of ursodeoxycholic acid, a bile acid with a long pharmacologic record in cholestasis. It is now widely sold as a supplement for general liver support and steroid-cycle protection. The pharmacology in cholestasis is well established, but the supplement-dose evidence for healthier livers is much thinner than marketing suggests.

What TUDCA actually is

Ursodeoxycholic acid (UDCA) is a naturally occurring secondary bile acid that humans produce in small amounts and that bears used to be hunted for medicinally. TUDCA is UDCA conjugated to taurine — the form predominant in the bile of certain bear species. Conjugation increases water solubility, alters enterohepatic recycling, and shifts the bile-acid pool toward less cytotoxic hydrophilic species. Both UDCA and TUDCA reduce ER (endoplasmic reticulum) stress in hepatocytes via mechanisms independent of bile flow itself.

Pharmacologic record in cholestasis

UDCA is the standard of care for primary biliary cholangitis and is used adjunctively in intrahepatic cholestasis of pregnancy, cystic-fibrosis-related liver disease, and progressive familial intrahepatic cholestasis. TUDCA has been compared head-to-head with UDCA in primary biliary cholangitis at equimolar doses and produced equivalent improvements in liver enzymes (ALT, ALP, GGT) at lower doses, with one small Italian trial showing slightly better tolerability [1].

A pivotal trial in cholestasis of pregnancy reported that TUDCA improved bile acid concentrations and ALT levels comparably to UDCA, with both arms outperforming placebo for maternal pruritus [2]. These are pharmacologic, prescription-dose trials — typically 500–1500 mg/day — not consumer supplement use.

Insulin sensitivity and ER stress

A small proof-of-concept human study reported that TUDCA at 1750 mg/day for four weeks improved hepatic and muscle insulin sensitivity in obese subjects without significant adverse effects, with mechanistic data implicating reduced ER stress [3]. This generated interest in TUDCA as a metabolic-health agent, but the trial is small, single-center, and has not been definitively reproduced at scale.

Use as a steroid-cycle 'on-cycle support' supplement

Anabolic-androgenic steroid users frequently use TUDCA to mitigate cholestatic injury from oral 17-alpha-alkylated androgens. The biological rationale is reasonable — these compounds produce drug-induced cholestasis to which bile-acid hydrophilic shifts plausibly offer protection — but published human evidence specifically for AAS hepatoprotection is essentially absent. Use sits well downstream of any controlled data.

Doses people actually take

Cholestasis trials have used 250–1500 mg/day in two or three divided doses. Consumer supplements commonly contain 250–500 mg per capsule and labels often suggest one to two capsules daily. There is no evidence that doses below 250 mg/day produce meaningful changes in bile acid composition or liver enzymes in people with healthy livers.

Safety, tolerability, and interactions

TUDCA is generally well tolerated. The most common adverse effects are diarrhea, abdominal discomfort, and dose-dependent loose stools. Theoretical interactions include reduced absorption of aluminum-containing antacids and altered absorption of cyclosporine; clinically relevant interactions with most common medications are uncommon. Pregnancy data are limited outside the cholestasis-of-pregnancy indication.

The bottom line

TUDCA has a real pharmacologic case in cholestatic liver disease and a thin but plausible mechanistic case in metabolic health. As a general liver-support supplement for people without disease, the human evidence does not yet justify routine use, and it remains a prescription pharmaceutical in some jurisdictions. Discuss with a clinician before adding it to medication regimens, particularly statins, oral contraceptives, or hepatotoxic drugs.